A detailed history of Primecap Management CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Primecap Management CO holds 1,164,610 shares of ZNTL stock, worth $4.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,164,610
Previous 1,023,350 13.8%
Holding current value
$4.59 Million
Previous $15.5 Million 18.39%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$10.83 - $16.49 $1.53 Million - $2.33 Million
141,260 Added 13.8%
1,164,610 $18.4 Million
Q4 2023

Feb 09, 2024

SELL
$9.84 - $20.13 $102,336 - $209,352
-10,400 Reduced 1.01%
1,023,350 $15.5 Million
Q3 2023

Nov 13, 2023

SELL
$19.63 - $28.29 $1.52 Million - $2.19 Million
-77,400 Reduced 6.97%
1,033,750 $20.7 Million
Q2 2023

Aug 11, 2023

SELL
$17.41 - $30.05 $309,375 - $533,988
-17,770 Reduced 1.57%
1,111,150 $31.3 Million
Q1 2023

May 15, 2023

SELL
$16.14 - $24.94 $20,175 - $31,175
-1,250 Reduced 0.11%
1,128,920 $19.4 Million
Q4 2022

Feb 13, 2023

SELL
$18.07 - $25.6 $895,007 - $1.27 Million
-49,530 Reduced 4.2%
1,130,170 $22.8 Million
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $248,829 - $390,279
-12,300 Reduced 1.03%
1,179,700 $25.6 Million
Q2 2022

Aug 11, 2022

SELL
$17.91 - $52.25 $297,126 - $866,827
-16,590 Reduced 1.37%
1,192,000 $33.5 Million
Q1 2022

May 11, 2022

SELL
$41.58 - $80.89 $1.87 Million - $3.64 Million
-45,050 Reduced 3.59%
1,208,590 $55.8 Million
Q4 2021

Feb 11, 2022

SELL
$66.92 - $84.79 $5.49 Million - $6.95 Million
-81,980 Reduced 6.14%
1,253,640 $105 Million
Q3 2021

Nov 12, 2021

SELL
$46.83 - $73.5 $608,321 - $954,765
-12,990 Reduced 0.96%
1,335,620 $89 Million
Q2 2021

Aug 10, 2021

BUY
$37.41 - $62.25 $493,063 - $820,455
13,180 Added 0.99%
1,348,610 $71.7 Million
Q1 2021

May 14, 2021

SELL
$35.69 - $52.72 $1.29 Million - $1.91 Million
-36,260 Reduced 2.64%
1,335,430 $57.9 Million
Q4 2020

Feb 08, 2021

SELL
$31.71 - $57.97 $350,712 - $641,148
-11,060 Reduced 0.8%
1,371,690 $71.2 Million
Q3 2020

Nov 13, 2020

BUY
$27.03 - $47.97 $19.5 Million - $34.7 Million
722,800 Added 109.52%
1,382,750 $45.2 Million
Q2 2020

Aug 13, 2020

BUY
$23.2 - $54.8 $15.3 Million - $36.2 Million
659,950 New
659,950 $31.7 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $225M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.